Related Experiment Video

Updated: Apr 8, 2026

An Experimental System to Study Mechanotransduction in Fetal Lung Cells
09:35

An Experimental System to Study Mechanotransduction in Fetal Lung Cells

Published on: February 16, 2012

13.4K

PP162. sFlt-1 controlled by CPAP in a pregnant patient with chronic hypertension

A L Daly1, A Robertson1, P Johnson2

  • 1University of Western Sydney, Sydney, Australia.

Pregnancy Hypertension
|June 25, 2015
PubMed

Insights

Sleep disordered breathing (SDB) in pregnant women with hypertension is linked to higher sFlt-1 levels. Continuous positive airway pressure (CPAP) treatment for SDB may reduce these levels, potentially lowering preeclampsia risk and severity.

Area of Science:

  • Obstetrics and Gynecology
  • Sleep Medicine
  • Cardiovascular Research

Background:

  • Preeclampsia is a major global cause of maternal and infant mortality.
  • Sleep disordered breathing (SDB) is increasingly investigated for its role in preeclampsia pathogenesis, potentially via placental hypoxia.
  • Soluble fms-like tyrosine kinase-1 (sFlt-1) is a key preeclampsia biomarker, indicating disease severity.

Purpose of the Study:

  • To investigate the impact of continuous positive airway pressure (CPAP) treatment for SDB on sFlt-1 levels during pregnancy.
  • To explore the relationship between SDB, hypertensive disorders, and sFlt-1 in pregnant women.

Main Methods:

  • Recruitment of four pregnant women from Campbelltown Hospital outpatient clinic in early 2011.
  • Measurement of sFlt-1 levels using ELISA in participants with and without hypertensive disorders and/or SDB.

Main Results:

  • Pregnant women with SDB and chronic hypertension or preeclampsia exhibited elevated sFlt-1 levels.
  • A greater percentage increase in sFlt-1 was observed in these women.
  • CPAP treatment appeared to mitigate the increase in sFlt-1 levels.

Conclusions:

  • Untreated SDB in women with chronic hypertension was associated with elevated sFlt-1.
  • This study demonstrates feasibility for larger research into CPAP's potential benefits for sFlt-1 levels and preeclampsia risk/severity.
  • Further investigation is warranted to validate the hypothesis that CPAP treatment positively influences sFlt-1 and reduces preeclampsia complications.
Abstract

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.4K
Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs05:40

Continuous Telemetric In Utero Tracheal Pressure Measurements in Fetal Lambs

Published on: December 22, 2023

660

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
595
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
776
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
566
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
658
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
615